Gasdermin: a novel therapeutic target for tumour treatment by activating anti-tumour immunity
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2059-3635
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Gasdermin: a novel therapeutic target for tumour treatment by activating anti-tumour immunity ; volume:5 ; number:1 ; day:13 ; month:5 ; year:2020 ; pages:1-2 ; date:12.2020
Signal transduction and targeted therapy ; 5, Heft 1 (13.5.2020), 1-2, 12.2020
- Urheber
-
Fu, Caiyun
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41392-020-0180-4
- URN
-
urn:nbn:de:101:1-2020072019182748343725
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Fu, Caiyun
- SpringerLink (Online service)
Ähnliche Objekte (12)
Acid affairs in anti-tumour immunity
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth
Glutarate regulates T cell metabolism and anti-tumour immunity
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity
Interleukin-35 promotes progression of prostate cancer and inhibits anti-tumour immunity
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
Small tumour microparticle enhances drug delivery efficiency and therapeutic antitumour efficacy
Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response
RIPK1‐mediated immunogenic cell death promotes anti‐tumour immunity against soft‐tissue sarcoma
Inhibiting glucocorticoid receptor signalling in tumour-associated macrophages for anti-tumour immune response
TT-232: An Anti-tumour and Anti-inflammatory Peptide Therapeutic in Clinical Development
Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cells
Acid affairs in anti-tumour immunity
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth
Glutarate regulates T cell metabolism and anti-tumour immunity
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity
Interleukin-35 promotes progression of prostate cancer and inhibits anti-tumour immunity
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
Small tumour microparticle enhances drug delivery efficiency and therapeutic antitumour efficacy
Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response
RIPK1‐mediated immunogenic cell death promotes anti‐tumour immunity against soft‐tissue sarcoma
Inhibiting glucocorticoid receptor signalling in tumour-associated macrophages for anti-tumour immune response
TT-232: An Anti-tumour and Anti-inflammatory Peptide Therapeutic in Clinical Development
Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cells
Acid affairs in anti-tumour immunity
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth
Glutarate regulates T cell metabolism and anti-tumour immunity
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity
Interleukin-35 promotes progression of prostate cancer and inhibits anti-tumour immunity
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
Small tumour microparticle enhances drug delivery efficiency and therapeutic antitumour efficacy
Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response
RIPK1‐mediated immunogenic cell death promotes anti‐tumour immunity against soft‐tissue sarcoma
Inhibiting glucocorticoid receptor signalling in tumour-associated macrophages for anti-tumour immune response
TT-232: An Anti-tumour and Anti-inflammatory Peptide Therapeutic in Clinical Development